• 出版社/出版日：Mordor Intelligence / 2021年7月26日
|Single User||￥480,250 (USD4,250)||▷ お問い合わせ|
|Team User||￥536,750 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥847,500 (USD7,500)||▷ お問い合わせ|
・競争状況（Abbott Laboratories、Danaher Corporation (Beckman Coulter, Inc)、Becton, Dickinson and Company、Bio Rad Laboratories Inc.、F. Hoffmann-La Roche Ltd、Luminex Corporation、Nihon Kohden Corporation、Qiagen NV、Siemens Healthineers、Thermo Fisher Scientific, Inc.、Grifols SA、Johnson & Johnson (Janssen Diagnostics BVBA)、Immucor, Inc.、F. Hoffmann-La Roche Ltd.、Sysmex Corporation）
The Cell Surface Markers Detection market was estimated to grow at a CAGR of 8.2% during the forecast period.
The COVID-19 pandemic is expected to have a significant impact on the market. Cell surface markers refers to carbohydrates and proteins that are attached to the cell membrane, thus allowing cell surface markers to play a crucial role in intercellular signaling. Many research projects are being carried out that involves the interaction of COVID-19 antibodies with cell surface markers. For example, in February 2021, a research article titled, ‘COVID-19 Impairs Immune Response to Candida albicans’ was published in Frontiers in Immunology. In the research paper, the cell surface marker expression on the monocytes of COVID-19 patients were studied and compared with healthy controls. The study found an increased rate of fungal coinfections during COVID-19 in patients. Rate of secondary fungal infections increase in many COVID-19 patients due to their decrease in immunity. Thus, use of cell surface markers to study fungal infection is expected to boost growth. Such initiatives help to drive a better understanding of the disease leading to innovative ways to find a cure. More such research projects are being conducted across the globe where cell surface markers are used to study the effect of COVID-19. Thus, developments such as these are expected to boost the market growth.
The major factors that are driving the market growth include the increasing demand for precision medicine, increased use of diagnostics, and technological advances related to increased throughput and automation. For example, over 200 cell-surface markers have been identified as being overexpressed in lung cancers. These include markers like Cytokeratin fragment 21-1 and EGFR gene mutation. Diagnostic procedures are used to detect the presence of tumor cells in the blood through these markers. Increase in the number of cancer cases across the world is expected to have a positive impact on the demand for biomarkers, thus boosting the growth of cell surface markers detection market. For instance, according to the Globocan 2020 report, the total number of breast cancer in 2020 was 2,261,419 followed by lung cancer at 2,206,771 cases and prostrate cancer at 1,414,259 cases. Since cell surface markers serve as monograms to help identify and classify cells, the proteins expressed on the surface of cancerous cells serve as markers of specific tumour types. This molecule identification helps in disease diagnoses, to find direct treatment for the disease, drug discovery, and has many other uses. This is expected to boost market growth. There are many companies that are involved in marker preparation which is likely to boost market growth. For instance, Becton, Dickinson and Company manufactures the BD Lyoplate Human Cell Surface Marker Screening Panel for use in research laboratories. The BD Lyoplate Human Cell Surface Marker Screening panel can be used for screening primary cells or tissues, cell lines, and is compatible for use with flow cytometry and bioimaging technology platforms. Such innovative products with wide variety of applications is expected to boost market growth.
Key Market Trends
Flow Cytometry Segment is Expected to Grow at Fastest Rate
The Flow Cytometry technique is used to detect the presence of cell types within a population. It is conducted by passing single cells through a highly focused laser. Antibodies that are specific to cell surface markers of interest are added to a sample and are then allowed to bind with the cells. These antibodies are coupled with fluorochromes which have a characteristic of emitting light at various wavelengths. The cell population is then passed through a laser, and the process excites the fluorochromes and captures the light that is emitted. The cells can then be subsequently sorted into subpopulations based on the markers present through a series of histograms and dot plots called a gating strategy. Cell surface markers that are expressed on the cell surface can be used to define cell subtypes as well as function when they are labeled with fluorescent-labeled antibodies and analyzed by flow cytometry. Clinical flow cytometry has the capacity to identify and quantify intracellular proteins associated with immune function. Cell surface-based flow cytometry is able to detect rare events, thus it is used extensively for detecting stem cells or cancerous cells. For example, cell surface-based flow cytometry can be used to detect CD341 hematopoietic stem cells in peripheral blood under resting conditions. It can also be used to evaluate minimal residual disease in patients with hematologic malignancy, such as hairy cell leukemia.
The role of flow cytometry has broadened to include the study of disorders of the immune system, including primary immunodeficiency disorders by using cell surface markers. For instance, cell-surface staining by using flow cytometry is often used for investigating lymphocyte clonality. T-cell clonality studies are particularly useful in evaluation of primary immunodeficiency disorders associated with a restricted T-cell. According to a study titled, ‘Flow cytometry: Surface markers and beyond’ published in JACI Online in 2019, the application of flow cytometry as a clinical laboratory method has evolved from the identification of cell-surface markers to characterizing intracellular proteins and providing multiple different approaches to assess immune function and characterizing and diagnosing immunologic disorders. Flow cytometry is used extensively in diagnosing cancer. Since the countries with high Human Development Index (HDI) invest more on healthcare, there is a greater number of cancer diagnostic tests that are conducted and more number of cancer cases are detected in these countries (International Agency for Research on Cancer, 2020). This is likely to boost market growth.
North America Dominates the Market and is Expected To Retain its Market Share During the Forecast Period
The North America region is the largest market for cell surface markers. Rapidly growing applications in disease diagnostics, the presence of well-established research institutions, and the biotech industry are primary reasons behind the large market size. The United States currently dominates the market for cell surface marker detection in North America and is expected to continue its stronghold for a few more years. High healthcare expenditure, a high technological adaptation rate, and an increasing focus on precise and timely diagnostics are driving the market growth in the United States. The United States has many companies operating in this sector due to which demand from the country is expected to be robust during the forecast period. Some of the United States-specific companies include Nexcelom Bioscience LLC, Cofactor Genomics, Inc., Abbott Laboratories, Beckman Coulter, Inc., and many others. The increased product launches by these players is expected to boost market growth. For example, in November 2020, Bio-Rad Laboratories, Inc., a United States-based research and clinical diagnostic company, launched three StarBright Dyes specifically developed for flow cytometry. The dyes include StarBright Blue 700, StarBright Violet 440, and StarBright Violet 610, and they are fluorescent nanoparticles that are conjugated to Bio-Rad’s flow antibodies, providing maximal brightness and improved resolution. They can be used for detecting surface proteins in market detection. Initiatives like these by major players are likely to boost growth.
The global cell surface market detection market is comprised of many global players, especially in the instrument front. These companies include Becton, Dickinson and Company, Nihon Kohden Corporation, Luminex Corporation, Sysmex Corporation and Thermo Fisher Scientific, Inc. among others. Several biotech startups, however, are active in the reagent, consumables, and other niche fields. There is an ongoing trend of further consolidation with the acquisition of new technology being a major focus. There are also some instances of acquisition of product lines and brands between key market participants.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Use in Diagnostics
4.2.2 Technological Advances Related to Increased Throughput and Automation
4.2.3 Increasing Demand for Precision Medicine
4.3 Market Restraints
4.3.1 High Cost of Instruments
4.3.2 Complexity of Techniques
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1.1 Flow Cytometry
5.1.2 Hematology Analyzers
5.1.3 Cell Imaging Systems
5.1.4 Reagents and Kits
5.1.5 Other Products
5.2.1 Disease Diagnosis and Identification
5.2.2 Research and Drug Discovery
5.2.3 Other Applications
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Danaher Corporation (Beckman Coulter, Inc)
6.1.3 Becton, Dickinson and Company
6.1.4 Bio Rad Laboratories Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Luminex Corporation
6.1.7 Nihon Kohden Corporation
6.1.8 Qiagen NV
6.1.9 Siemens Healthineers
6.1.10 Thermo Fisher Scientific, Inc.
6.1.11 Grifols SA
6.1.12 Johnson & Johnson (Janssen Diagnostics BVBA)
6.1.13 Immucor, Inc.
6.1.14 F. Hoffmann-La Roche Ltd.
6.1.15 Sysmex Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS